A nationwide study of campylobacter jejuni and campylobacter coli bacteremia in Finland over a 10-year period, 1998-2007, with special reference to clinical characteristics and antimicrobial susceptibility

Clinical Infectious Diseases

Volumn 53, Issue 8, 2011, Pages

  Feodoroff, Benjamin ^a   Lauhio, Anneli ^b,c   Ellström, Patrik ^d   Rautelin, Hilpi ^a,c,d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; MEROPENEM; METRONIDAZOLE;

ADOLESCENT; ADULT; AGAR DILUTION; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BLOOD CULTURE; CAMPYLOBACTER COLI; CAMPYLOBACTER COLI BACTEREMIA; CAMPYLOBACTER JEJUNI; CAMPYLOBACTER JEJUNI BACTEREMIA; CHILD; CONTROLLED STUDY; FEMALE; FINLAND; GUILLAIN BARRE SYNDROME; HOSPITALIZATION; HUMAN; INFANT; INTERVERTEBRAL DISK DEGENERATION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MEDICAL RECORD REVIEW; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; BACTEREMIA; CAMPYLOBACTER COLI; CAMPYLOBACTER INFECTIONS; CAMPYLOBACTER JEJUNI; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; FEMALE; FINLAND; HOSPITALIZATION; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; SEASONS; YOUNG ADULT;

EID: 80052885384     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir509     Document Type: Article

References (35)

1. Blaser MJ. Epidemiologic and clinical features of Campylobacter jejuni infections. J Infect Dis 1997; 176:S103-5. (Pubitemid 27505870)
2. Rautelin H, Hänninen ML. Campylobacters: the most common bacterial enteropathogens in the Nordic countries. Ann Med 2000; 32:440-5.
3. European Food Safety Authority. The European Union summary report on trends and sources of zoonoses, zoonotic agents and foodborne outbreaks in 2009, Available at: http://www.efsa.europa.eu/en/efsajournal/pub/2090.htm. Accessed 28 March 2011.
4. Hannu T, Mattila L, Rautelin H, et al. Campylobacter-triggered reactive arthritis: a population-based study. Rheumatology 2002; 41:312-8. (Pubitemid 34537868)
5. McCarthy N, Giesecke J. Incidence of Guillain-Barré syndrome following infection with Campylobacter jejuni. Am J Epidemiol 2001; 153:610-4. (Pubitemid 32221717)
6. Tam CC, Rodrigues LC, Petersen I, Islam A, Hayward A, O'Brien SJ. Incidence of Guillain-Barré syndrome among patients with Campylobacter infection: a general practice research database study. J Infect Dis 2006; 194:95-7.
7. Samuel MC, Vugia DJ, Shallow S, et al. Epidemiology of sporadic Campylobacter infection in the United States and declining trend in incidence, FoodNet 1996-1999. Clin Infect Dis 2004; 38:S165-74. (Pubitemid 38553321)
8. Nielsen H, Hansen KK, Gradel KO, et al. Bacteraemia as a result of Campylobacter species: a population-based study of epidemiology and clinical risk factors. Clin Microbiol Infect 2010; 16:57-61.
9. Skirrow MB, Jones DM, Sutcliffe E, Benjamin J. Campylobacter bacteraemia in England and Wales, 1981-91. Epidemiol Infect 1993; 110:567-73. (Pubitemid 23217354)
10. Pacanowski J, Lalande V, Lacombe K, et al. Campylobacter bacteremia: clinical features and factors associated with fatal outcome. Clin Infect Dis 2008; 47:790-6.
11. Fernández-Cruz A, Munoz P, Mohedano R, et al. Campylobacter bacteremia: clinical characteristics, incidence, and outcome over 23 years. Medicine 2010; 89:319-30.
12. Reed RP, Friedland IR, Wegerhoff FO, Khoosal M. Campylobacter bacteremia in children. Pediatr Infect Dis J 1996; 15:345-8. (Pubitemid 26119276)
13. Pigrau C, Bartolome R, Almirante B, Planes AM, Gavalda J, Pahissa A. Bacteremia due to Campylobacter species: clinical findings and antimicrobial susceptibility patterns. Clin Infect Dis 1997; 25:1414-20. (Pubitemid 28022682)
14. Gazaigne L, Legrand P, Renaud B. Campylobacter fetus bloodstream infection: risk factors and clinical features. Eur J Clin Microbiol Infect Dis 2008; 27:185-9.
15. Feodoroff FB, Lauhio AR, Sarna SJ, Hänninen ML, Rautelin HI. Severe diarrhoea caused by highly ciprofloxacin-susceptible Campylobacter isolates. Clin Microbiol Infect 2009; 15:188-92.
16. Feodoroff B, Ellström P, Hyytiäinen H, Sarna S, Hänninen ML, Rautelin H. Campylobacter jejuni isolates in Finnish patients differ according to the origin of infection. Gut Pathog 2010; 2:22.
17. Linton D, Owen RJ, Stanley J. Rapid identification by PCR of the genus Campylobacter and of five Campylobacter species enteropathogenic for man and animals. Res Microbiol 1996; 147:707-18. (Pubitemid 26408348)
18. Denis M, Soumet C, Rivoal K, et al. Development of a m-PCR assay for simultaneous identification of Campylobacter jejuni and C. coli. Lett Appl Microbiol 1999; 29:406-10. (Pubitemid 30052890)
19. Gonzalez I, Grant KA, Richardson PT, Park SF, Collins MD. Specific identification of the enteropathogens Campylobacter jejuni and Campylobacter coli by using a PCR test based on the ceuE gene encoding a putative virulence determinant. J Clin Microbiol 1997; 35:759-63. (Pubitemid 27083878)
20. Linton D, Lawson AJ, Owen RJ, Stanley J. PCR detection, identification to species level, and fingerprinting of Campylobacter jejuni and Campylobacter coli direct from diarrheic samples. J Clin Microbiol 1997; 35:2568-72. (Pubitemid 27402662)
21. Clinical and Laboratory Standards Institute/NCCLS. Performance for antimicrobial susceptibility testing: fifteenth informational supplement. M100-S15. Wayne, PA: Clinical and Laboratory Standards Institute, 2005.
22. Clinical and Laboratory Standards Institute. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. Approved standard. M45-A. Wayne, PA: Clinical and Laboratory Standards Institute, 2006.
23. National Antimicrobial Resistance Monitoring System. NARMS 2006 executive report. Available at: http://www.fda.gov/AnimalVeterinary/SafetyHealth/ AntimicrobialResistance/NationalAntimicrobialResistanceMonitoringSystem/ ucm182896.htm. Accessed 14 April 2011.
24. National Antimicrobial Resistance Monitoring System. 2002. NARMS retail meat annual report. Available at:http://www.fda.gov/Animal-Veterinary/ SafetyHealth/AntimicrobialResistance/ NationalAntimicrobialResistanceMonitoringSystem/ucm091417.htm. Accessed 14 April 2011.
25. Hariharan H, Sharma S, Chikweto A, Matthew V, DeAllie C. Antimicrobial drug resistance as determined by the E-test in Campylobacter jejuni, C. coli, and C. lari isolates from the ceca of broiler and layer chickens in Grenada. Comp Immunol Microbiol Infect Dis 2009; 32:21-8.
26. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-83. (Pubitemid 17055592)
27. National Public Health Institute. National infectious diseases register, Available at: http://www3.ktl.fi/stat/. Accessed 5 April 2011.
28. National Institute for Health and Welfare. Infectious diseases in Finland 1995-2009, Available at: http://www.thl.fi/thl-client/pdfs/d6d63c66-9690-4f4d- 9ee1-319bb5648eaf. Accessed 15 April 2011.
29. Nakari UM, Huovinen E, Kuusi M, Siitonen A. Population-based surveillance study of Campylobacter infections in Finland. Epidemiol Infect 2010; 138:1712-8.
30. Schönberg-Norio D, Hänninen ML, Katila ML, et al. Activities of telithromycin, erythromycin, fluoroquinolones, and doxycycline against Campylobacter strains isolated from Finnish subjects. Antimicrob Agents Chemoter 2006; 50:1086-8.
31. Engberg J, Neimann J, Nielsen EM, Aerestrup FM, Fussing V. Quinolone-resistant Campylobacter infections: risk factors and clinical consequences. Emerg Infect Dis 2004; 10:1056-63. (Pubitemid 38697698)
32. Nelson JM, Smith KE, Vugia DJ. Prolonged diarrhea due to ciprofloxacin-resistant Campylobacter infection. J Infect Dis 2004; 190: 1150-7. (Pubitemid 39186803)
33. Helms M, Simonsen J, Olsen KE, Molbak K. Adverse health events associated with antimicrobial drug resistance in Campylobacter species: a registry-based cohort study. J Infect Dis 2005; 191:1050-5. (Pubitemid 40404362)
34. Ternhag A, Asikainen T, Giesecke J, Ekdahl K. A meta-analysis on the effects of antibiotic treatment on duration of symptoms caused by infection with Campylobacter species. Clin Infect Dis 2007; 44: 696-700.
35. Lemaire X, Dehecq C, Cattoen C. Spondylodiscitis and an aortic aneurysm due to Campylobacter coli. Ann Clin Microbiol Antimicrob 2010; 9:8.